NO20083588L - Improved crystalline material - Google Patents

Improved crystalline material

Info

Publication number
NO20083588L
NO20083588L NO20083588A NO20083588A NO20083588L NO 20083588 L NO20083588 L NO 20083588L NO 20083588 A NO20083588 A NO 20083588A NO 20083588 A NO20083588 A NO 20083588A NO 20083588 L NO20083588 L NO 20083588L
Authority
NO
Norway
Prior art keywords
crystalline material
improved crystalline
crystalline form
improved
phonoxy
Prior art date
Application number
NO20083588A
Other languages
English (en)
Inventor
Neeraj Garg
Ramakrishnan Chidambaram
Ake Rasmusson
Original Assignee
Karobio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karobio Ab filed Critical Karobio Ab
Publication of NO20083588L publication Critical patent/NO20083588L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Organic Insulating Materials (AREA)

Abstract

Det beskrives nye krystallinske former av 3-[[3,5-dibrom-4-[4-hydroksy-3-(1-metyletyl)-fenoksy]-fenyl]amino]-3-okso-propansyre, der de krystallinske former karakteriseres ved et pulverrøntgendiffraksjonsmønster med hovedtopper med enten 2?=16,1±0,2, 20,1±0,2, 20,7±0,2 og 24,2±0,2; eller 2?=9,0±0,2, 14,7 ±0,2, 19,6±0,2, 21,6±0,2 og 24,3±0,2.
NO20083588A 2006-03-28 2008-08-19 Improved crystalline material NO20083588L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0606201.2A GB0606201D0 (en) 2006-03-28 2006-03-28 Improved crytalline material
PCT/EP2007/002687 WO2007110225A1 (en) 2006-03-28 2007-03-27 Improved crystalline material

Publications (1)

Publication Number Publication Date
NO20083588L true NO20083588L (no) 2008-11-12

Family

ID=36424732

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083588A NO20083588L (no) 2006-03-28 2008-08-19 Improved crystalline material

Country Status (16)

Country Link
US (1) US20090239951A1 (no)
EP (2) EP2368873A1 (no)
JP (1) JP2009531358A (no)
KR (1) KR20090014342A (no)
CN (1) CN101421229A (no)
AT (1) ATE550314T1 (no)
AU (1) AU2007229718A1 (no)
BR (1) BRPI0710120A2 (no)
CA (1) CA2642872A1 (no)
GB (1) GB0606201D0 (no)
MX (1) MX2008012393A (no)
NO (1) NO20083588L (no)
NZ (1) NZ570684A (no)
RU (1) RU2444513C2 (no)
WO (1) WO2007110225A1 (no)
ZA (1) ZA200807596B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
DK2695611T3 (en) 2012-08-06 2015-01-05 Wolff August Gmbh & Co Kg Arzneimittel Dr Eprotirome for use in the prevention and / or treatment of hair disorders and their compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3450751A (en) * 1963-06-15 1969-06-17 Noguchi Inst The Continuous optical resolution of racemic glutamic acid or its salts
GB9220137D0 (en) * 1992-09-23 1992-11-04 Pfizer Ltd Therapeutic agents
KR100740383B1 (ko) * 2000-02-17 2007-07-16 브리스톨-마이어스스퀴브컴파니 갑상선 수용체에 대한 아닐린 유도 리간드
SK13762002A3 (sk) * 2000-03-31 2004-01-08 Pfizer Products Inc. Malonámové kyseliny a ich deriváty ako ligandy tyreoideálnych receptorov
AU4884701A (en) * 2000-05-12 2001-11-20 Kissei Pharmaceutical Co. Ltd. Malonanilic acid derivatives, medicinal compositions containing the same and usethereof
WO2002083480A1 (en) 2001-04-12 2002-10-24 Mtd Products Inc Four-wheel steering system
JP4225791B2 (ja) * 2001-05-18 2009-02-18 キッセイ薬品工業株式会社 肝癌の予防または再発抑制剤
US6806381B2 (en) * 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor

Also Published As

Publication number Publication date
ATE550314T1 (de) 2012-04-15
CN101421229A (zh) 2009-04-29
EP2004593A1 (en) 2008-12-24
US20090239951A1 (en) 2009-09-24
ZA200807596B (en) 2009-11-25
CA2642872A1 (en) 2007-10-04
WO2007110225A1 (en) 2007-10-04
AU2007229718A1 (en) 2007-10-04
KR20090014342A (ko) 2009-02-10
MX2008012393A (es) 2009-03-02
RU2008142528A (ru) 2010-05-10
EP2368873A1 (en) 2011-09-28
GB0606201D0 (en) 2006-05-10
EP2004593B1 (en) 2012-03-21
NZ570684A (en) 2011-07-29
JP2009531358A (ja) 2009-09-03
RU2444513C2 (ru) 2012-03-10
BRPI0710120A2 (pt) 2011-08-02

Similar Documents

Publication Publication Date Title
NO20083588L (no) Improved crystalline material
BRPI0819802A2 (pt) "composição fungicida, composto e método para controlar uma doença"
FR2921376B1 (fr) Compose styryl tetrahydroquinolinium thiol/disulfure, procede d'eclaircissement des matieres keratiniques a partir de ce colorant
IL242538A (en) Composition containing (s) –n– (3– chloro – 4 – cyanophenyl) –3– (4 – cyanophenoxy) -2
IL223412A0 (en) Process for producing pesticidal benzamide compounds
TW200716558A (en) Heteroaroyl-substituted serineamides
BRPI0811653A2 (pt) "material não-tecido permeável à líquido e método para a produção do mesmo"
HK1199885A1 (en) Crystalline forms of (3s)-3-[n-(n-(2-tert- butylphenyl)oxamyl)alaniwyl]amino-5-(2,3,5,6-tetrafluoro phenoxy)-4-0x0penta noic acid (3s)-3-[n-(n-(2-))]-5-(2356- )-4-
CL2008000322A1 (es) Proceso para la preparacion de un compuesto derivado de 2-tiazol-2-il-quinolina; compuestos intermediarios; y proceso de preparacion de dichos compuestos intermediarios.
SI2076501T1 (sl) Kristalinične oblike 3-(5-(2-florofenil)-1,2,4) oksadiazol-3-il)-benzojske kisline
HK1160139A1 (en) Biocidal boronophthalide compounds 2-[c]
BRPI0804994A2 (pt) forma cristalina vi de agomelatina, um processo para a sua preparação e composições farmacêuticas contendo-a
BRPI0603059A (pt) forma cristalina v de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
IL189829A0 (en) A process for preparing oxazolidine protected aminodiol compounds useful as intermediates to florfenicol
ZA201100422B (en) 1,2-benzisothiazole compounds useful for combating animal pests
HRP20130597T1 (en) A diphosphate salts of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
BRPI0519578A2 (pt) pirimidinas substituÍdas
BRPI0810822A2 (pt) Composto de amida e o emprego do mesmo para o controle de doenças de plantas
BRPI0914400A2 (pt) "processo para a síntese de um composto"
FR2922285B1 (fr) Butee d'embrayage comprenant une portee d'actionnement rotulante
ZA200900208B (en) Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound
WO2011108752A3 (en) Plant disease controlling composition and method for controlling plant disease
FR2933397B1 (fr) Procede de fabrication d'une structure de garnissage avec maitrise des parametres de la synthese hydrothermale
BRPI0914350A2 (pt) "processo para a síntese de um composto"
ATE503473T1 (de) 3-(2,2,2-trimethylhydrazinium) propionat-salze zur behandlung des myokardinfarktes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application